Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lack of Benefit of Lactobacillus reuteri DSM 17938 as an Addition to the Treatment of Functional Constipation.

  • 2018-12
  • Journal of pediatric gastroenterology and nutrition 67(6)
    • Oleg Jadrešin
    • Sara Sila
    • Ivana Trivić
    • Zrinjka Mišak
    • Iva Hojsak
    • Sanja Kolaček

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 33
Population
33 children (12 girls, median age 4.5 years, range 2-16)
Methods
single-center randomized, double-blind, placebo-controlled study; intervention group received L reuteri DSM 17983 and lactulose, placebo group received placebo and lactulose
Blinding
Double-blind
Funding
Unclear
The aim of this study was to investigate the role of Lactobacillus reuteri DSM 17983 in the treatment of functional constipation in children. The trial was a single-center randomized, double-blind, placebo-controlled study. Patients were allocated into the 2 groups; intervention group which received L reuteri DSM 17983 and lactulose and placebo group which received placebo and lactulose. Due to small recruitment rate study was terminated prematurely; therefore, only 33 children (12 girls, median age 4.5 years, range 2-16) were randomized. There was no difference between groups in the stool frequency, stool consistency, pain, soiling rate and dose of the lactulose. This study found that L reuteri DSM 17938 adds no benefit to the treatment of constipation in children. Due to small sample size, these results, however, should be interpreted with caution.

Research Insights

Back to top